Aprea Therapeutics, Inc. (NASDAQ:APRE) Sees Significant Increase in Short Interest

Aprea Therapeutics, Inc. (NASDAQ:APRE) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 260,110 shares, an increase of 623.6% from the January 15th total of 35,947 shares. Approximately 4.3% of the company’s stock are sold short. Based on an average daily volume of 11,506,003 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 11,506,003 shares, the days-to-cover ratio is presently 0.0 days. Approximately 4.3% of the company’s stock are sold short.

Aprea Therapeutics Stock Performance

APRE stock traded down $0.02 during mid-day trading on Tuesday, hitting $0.64. The company had a trading volume of 135,204 shares, compared to its average volume of 4,519,952. The firm has a market cap of $4.47 million, a PE ratio of -0.30 and a beta of 1.48. The stock’s fifty day moving average price is $0.88 and its two-hundred day moving average price is $1.27. Aprea Therapeutics has a 12 month low of $0.55 and a 12 month high of $3.72.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.36). Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%.The firm had revenue of $0.00 million during the quarter. Equities analysts anticipate that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Insider Transactions at Aprea Therapeutics

In other news, Director Marc Duey purchased 21,459 shares of the business’s stock in a transaction on Wednesday, December 10th. The stock was purchased at an average price of $1.17 per share, for a total transaction of $25,107.03. Following the completion of the purchase, the director directly owned 256,155 shares in the company, valued at $299,701.35. The trade was a 9.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 13.63% of the company’s stock.

Analysts Set New Price Targets

APRE has been the topic of a number of recent research reports. Wedbush lowered their target price on Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday. Zacks Research lowered Aprea Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, January 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $4.00 target price (down from $5.00) on shares of Aprea Therapeutics in a report on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $5.50.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.